A Trial of SAMe for Treatment-Resistant Bipolar Depression

Summary

S-adenosyl-L-methionine (SAMe) is a dietary supplement with antidepressant properties. SAMe's mechanism of action remains unclear, but it appears to be distinct from that of conventional antidepressants. The purpose of this study is to examine the effect of these properties on the mood of bipolar subjects with persistent major depression that has been unresponsive to standard pharmacotherapy.

Timeline

Start

2008-09

Primary completion

2011-09

Completion

2011-09

Outcome

Missed primary endpoint

registry analysis (superiority or other test); SAMe vs Placebo; p = 1.0; Regression, Linear NCT00762268 ↗

Publications

• Results Murphy BL, Babb SM, Ravichandran C, Cohen BM. Oral SAMe in persistent treatment-refractory bipolar depression: a double-blind, randomized clinical trial. J Clin Psychopharmacol. 2014 Jun;34(3):413-6. doi: 10.1097/JCP.0000000000000064. No abstract available.

Drugs

Indications